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The lung serves as a primary site for xeno-
biotic metabolism, and many xenobiotics are
substrates for cytochrome P450 catalyzed oxi-
dations. Notably, the lung is composed of
> 40 different cell types with different levels of
metabolic competence (Ding and Kaminsky
2003). Alveolar macrophages and bronchial
epithelial cells are part of > 40 different cell
types in lung tissue and differ in their biologi-
cal functions (Hocking and Golde 1979;
Hukkanen et al. 2002). Indeed alveolar
macrophages clear the airways of tobacco
smoke particles and therefore constitute an
important defense mechanism (Drath et al.
1979). Furthermore, the lung epithelium
takes part in the detoxification of tobacco
smoke through metabolic activation by
phase I and phase II enzymes (Crawford et al.
1998; Han et al. 2005). Although a number
of CYP isoforms have been identified in
human lung tissue, a comprehensive survey of
most human pulmonary xenobiotic metabo-
lizing enzymes in different human lung tissue
compartments has not been performed.
Tobacco smoke constitutes a complex mix-
ture of thousands of toxicants, some of which
require tissue-specific activation to become
genotoxic carcinogens and others become
metabolically activated poisons (Smith et al.
2003; Yamazaki et al. 1992). For smokers, the
risk of developing lung cancer has been shown
to be, at least in part, dependent on pulmonary
metabolism of smoke constituents (Rubin
2001). Particular evidence stems from studies
with smokers in which genetic polymorphisms
of certain xenobiotic metabolizing enzymes
were linked to the development of lung cancer
(Bartsch et al. 2000; London et al. 1999).
Currently available data suggest that genetic
variability in coding sequences of P450
enzymes, antioxidants, or DNA repair genes
contribute to the risk of developing broncho-
genic carcinomas (Caporaso 2002).
Cigarette smoke may affect the capacity of
lung tissue to dispose of foreign chemicals by
changing expression and coded activity of
xenobiotic metabolizing enzymes. Additionally,
cigarette smoke may affect the pharmaco-
kinetics of inhaled drugs by modulating activity
of speciﬁc drug metabolizing enzymes (Durak
et al. 1996).
Therefore, knowledge of expression and
activity of xenobiotic and drug metabolizing
enzymes in lung tissue of smokers gives us a
better understanding of metabolically induced
toxicity of tobacco smoke constituents and
allows us to assess the capacity for tissue
specific detoxification.
We investigated the gene expression of
19 cytochrome P450 monooxygenases (CYPs)
and 3 flavin-containing monooxygenases
(FMOs), as well as uridine diphosphate glu-
curonosyltransferase (UGT) 2A1 (UGT2A1),
epoxide hydrolase (EPHX1), glutathione-S-
transferase (GST) A2 (GSTA2), GSTP1, and
GSTM1 in lung cells obtained from broncho-
alveolar lavage (BAL) fluid and in bronchial
biopsies (BBs) of smokers (n = 8) and non-
smokers (n = 10). 
Additionally, transcriptional regulation of
CYPs depends, at least in part, on promoter
activation through binding of transcription
factors and nuclear receptors to cognate DNA
recognition sites (Borlak and Thum 2001;
(Pascussi et al. 2003). We therefore studied
expression of the aryl hydrocarbon receptor
(AHR), constitutive androstane receptor
(CAR), pregnane X receptor (PXR), liver
X receptor (LXR), and glucocorticoid receptor
(GR) (Gibson et al. 2002; Tirona et al. 2003)
for their established role in CYP gene regula-
tion in BAL cells and BBs derived from
smokers and nonsmokers.
Methods
Study subjects. All subjects were volunteers
and gave written consent after being fully
informed about the purpose and nature of the
study. The study was approved by the Ethical
Committee of Hannover Medical School. 
Ten nonsmokers and eight smokers were
enrolled. All subjects had no history of allergic
or other diseases. Only subjects with forced
expiratory volume in 1 sec (FEV1) > 75% (pre-
dicted); normal electrocardiogram, differential
blood cell count, blood coagulation, serum
parameters (gamma-glutamyl-transferase,
aspartate aminotransferase, alanine aminotrans-
ferase, urea, creatinine, sodium, potassium,
IgE); and negative skin-prick test (ALK-
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BACKGROUND: Cytochrome P450 monooxygenases (CYP) play an important role in the defense
against inhaled toxicants, and expression of CYP enzymes may differ among various lung cells and
tissue compartments.
METHODS: We studied the effects of tobacco smoke in volunteers and investigated gene expression
of 19 CYPs and 3 ﬂavin-containing monooxygenases, as well as isoforms of gluthathione S-trans-
ferases (GST) and uridine diphosphate glucuronosyltransferases (UGT) and the microsomal epoxide
hydrolase (EPHX1) in bronchoalveolar lavage cells and bronchial biopsies derived from smokers
(n = 8) and nonsmokers (n = 10). We also investigated gene expression of nuclear transcription fac-
tors known to be involved in the regulation of xenobiotic metabolism enzymes.
RESULTS: Gene expression of CYP1A1, CYP1B1, CYP2S1, GSTP1, and EPHX1 was induced in
bronchoalveolar lavage cells of smokers, whereas expression of CYP2B6/7, CYP3A5, and UGT2A1
was repressed. In bronchial biopsies of smokers, CYP1A1, CYP1B1, CYP2C9, GSTP1, and GSTA2
were induced, but CYP2J2 and EPHX1 were repressed. Induction of CYP1A1 and CYP1B1 tran-
script abundance resulted in increased activity of the coded enzyme. Finally, expression of the liver
X receptor and the glucocorticoid receptor was signiﬁcantly up-regulated in bronchoalveolar lavage
cells of smokers. 
CONCLUSIONS: We found gene expression of pulmonary xenobiotic metabolizing enzymes and certain
key transcription factors to be regulated in bronchoalveolar lavage cells and bronchial biopsies of
smokers. The observed changes demonstrate tissue speciﬁcity in xenobiotic metabolism, with likely
implications for the metabolic activation of procarcinogens to ultimate carcinogens of tobacco smoke.
KEY WORDS: cytochrome P450 monooxygenases, metabolism, smoking, transcription factors, xeno-
biotic metabolizing enzymes. Environ Health Perspect 114:1655–1661 (2006). doi:10.1289/ehp.8861
available via http://dx.doi.org/ [Online 19 July 2006]Germany) were included. The characteristics of
the study subjects are summarized in Table 1.
None of the subjects had records of drug
abuse; for females, pregnancy was excluded
before study participation. None of the sub-
jects suffered acute bronchitis 4 weeks before
bronchoscopy. Nonsmokers could not have
smoked a cigarette for at least 5 years.
Inclusion criteria for smokers were a minimum
consumption of 15 cigarettes/day for at least
2 years. Levels of cotinine, a stable metabolite
of nicotine, were measured in urine to estimate
current nicotine exposure. Only smokers with
cotinine levels ≥ 100 ng/mL and nonsmokers
with cotinine levels ≤ 25 ng/mL were included.
In addition, the interval between bron-
choscopy and smoking of the last cigarette
prior to bronchoscopy was 57–157 min.
Bronchoscopic procedure. Prior to bron-
choscopy, all subjects received atropine
(0.5 mg subcutaneously) and midazolam
(0.05–0.1 mg/kg). Lidocaine (maximum:
6 mg/kg) was given as a local anesthetic of the
upper and lower airways. Drug administra-
tion and timing was strictly controlled. The
bronchoscope (BF 160 P, Olympus Optical
Co. Europe GmbH, Hamburg, Germany)
was wedged into the medial segment of the
middle lobe, and BAL was performed with
6 × 20 mL sterile saline solution. Lavage ﬂuid
from the first 20 mL was discarded. After
lavage, the bronchoscope was passed to the
anterior segment of the left upper lobe and
three bronchial biopsies were taken distal
from the carina. The biopsy samples were
immediately placed in RNA isolation buffer
(Macherey-Nagel GmbH & Co. KG, Düren,
Germany), snap-frozen in liquid nitrogen,
and stored at –80°C to await further analysis. 
Processing of BAL cells. BAL ﬂuid samples
were processed as described previously (Krug
et al. 2001). Brieﬂy, cells were ﬁltered through
a 100-µm filter. An aliquot of the BAL cells
was used to determine the total count of
nucleated cells using a Neubauer hemo-
cytometer. After counting, two aliquots con-
taining 1 × 106 cells were separated, pelleted,
snap-frozen in liquid nitrogen, and stored at
–80°C until RNA isolation. Differential cell
counts were obtained from cytospin slides,
with 300 cells/slide being counted (Table 2). 
RNA isolation and reverse transcription.
RNA was isolated from BAL pellets (1 × 106
cells/pellet) and biopsy materials using the
Total RNA Isolation System (Macherey-
Nagel GmbH & Co. KG) according to the
manufacturer’s recommendation. Quality and
quantity of isolated RNA was assayed by
capillary electrophoresis (Bioanalyzer 2100;
Agilent Technologies Deutschland GmbH,
Böblingen, Germany) following the manufac-
turers instructions. We used 1 µg total RNA
from each sample for reverse transcription, as
described previously (Thum and Borlak
2002). The resulting cDNA was frozen at
–20°C until further experimentation.
Thermocycler reverse transcriptase-
polymerase chain reaction (RT-PCR). PCR
was carried out using a thermal cycler (T3;
Biometra GmbH, Goettingen, Germany) as
described previously (Thum and Borlak 2001).
In brief, the following PCR conditions were
used: denaturation, 94°C (45 sec); primer
annealing, 54–58°C (60 sec); and extension,
72°C (60 sec). Detailed oligonucleotide
sequence information is given in Table 3. We
checked for DNA contamination by direct
ampliﬁcation of RNA extracts before conver-
sion to cDNA. Any contamination of RNA
extracts with genomic DNA could therefore be
excluded. The optimal PCR cycles were
derived by studying PCR products at different
numbers of PCR cycles. As a consequence,
PCR-reactions were performed within the lin-
ear range of amplification, and transcript
expression levels were calculated as the ratio of
the gene of interest (numerator) versus an
established housekeeping gene (cyclophilin A,
denumerator). We observed no signiﬁcant dif-
ferences in the gene expression results when
experiments were repeated with the same
cDNA, indicating good reproducibility of the
method. Amplification products were sepa-
rated on a 1.5% agarose gel, stained with
ethidium bromide, photographed on a trans-
illuminator (Kodak Image Station 440; Kodak
GmbH, Stuttgart, Germany), and quantiﬁed
using the Kodak 1D 3.5 network software.
Ethoxyresorufin-O-demethylase (EROD)
assay. Immediately after bronchoscopy, approx-
imately 0.1 × 106 cells were separated from
BAL fluid and put into 500 µL Dulbecco’s
Thum et al.
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Table 2. Basic BAL ﬂuid data given as median (range).
Recovery Total cells Macrophages Neutrophils Lymphocytes Eosinophils
Subjects (n) (mL) (× 106)  Percent of cells No. (× 106) Percent of cells No. (× 106)  Percent of cells No. (× 106)  Percent of cells No. (× 106) 
Nonsmokers (10) 77.5 (60–88) 5.9 (2.5–7.0) 90 (84–95) 5.2 (2.2–6.7) 2 (1–3) 0.1 (0.1–0.2) 7 (3–13) 0.3 (0.1–0.8) 0 (0–1) 0 (0–0.1)
Smokers (8) 76.5 (62–86) 9.3 (5.3–23.6)** 90 (85–92) 8.1 (4.9–21.2)** 4 (1–8)** 0.5 (0.1–1.4)** 4.5 (3–5) 0.4 (0.2–1.2) 0 (0–4) 0 (0–0.3)
**p < 0.01 compared with nonsmokers.
Table 1. Subject characteristics. 
Subjects Age Sex FEV1 (% predicted) FEV1/FVC (%) Cigarettes/day Pack-years Cotinine (ng/mL) Interval (min)a
Nonsmokers (n = 10) 23 F 108.5 73.7 0 0 8.5 —
36 F 113.7 85.8 0 0 13.5 —
21 F 92.2 77.1 0 0 0 —
24 F 101.2 78.8 0 0 0 —
28 M 106.0 76.3 0 3.75 20.4 —
24 F 123.5 86.7 0 0 2.3 —
25 F 105.5 83.8 0 0 0 —
26 M 98.6 81.7 0 0 0 —
26 F 85.5 79.7 0 0 0 —
23 F 106.0 83.7 0 0 0 —
Median (range) 24.5 (21–36) — 105.8 (85.5–123.5) 80.7 (73.7–86.7) 0 (0) 0 (0–3.75) 0 (0–20.4) —
Smokers (n = 8) 28 M 107.6 85.2 20 13.0 194.8 87
30 M 98.1 75.8 20 3.0 175.8 137
22 F 113.2 83.2 20 7.0 400.0 157
30 M 95.4 73.5 20 13.0 241.4 88
29 M 89.2 78.6 20 2.5 156.8 93
27 M 108.2 74.6 25 15.0 310.0 136
26 M 99.0 83.7 20 12.0 369.0 88
45 M 77.2 75.3 20 31.0 102.8 70
Median (range) 28.5 (22–45) — 98.6 (77.2–113.2) 77.2 (73.5–85.2) 20 (20–25) 12.5 (2.5–31.0) 218.1 (102–400) 90.5 (70–157)
Abbreviations: F, female; M, male.
aTime interval between smoking the last cigarette to bronchoscopy. modiﬁed Eagle’s medium supplemented with
5% fetal calf serum and 2 mM glutamine.
Then, 7-ethoxyresoruﬁn (2 µM, Sigma-Aldrich
Chemie GmbH, Deisenhofen, Germany; dis-
solved in DMSO) and dicumarol (10 µM;
Sigma-Aldrich Chemie GmbH) were added,
and cells were incubated at 37°C for 4 hr and
centrifuged for 5 min (1,200 × g, 4°C). The
resulting supernatant was snap-frozen in liquid
nitrogen and stored at –80°C to await ﬂuores-
cence detection essentially as described by
Grant et al. (1987). Samples (250 µL) were
treated with 250 µL ammonium acetate (pH
4.5), and aliquots were treated with 100 U/mL
β-glucuronidase (Sigma-Aldrich Chemie
GmbH) overnight at 37°C to assay product
release of β-glucuronide conjugates. After addi-
tion of 500 µL glycine buffer (pH 10.3),
fluorometric analysis was carried out on a
spectroﬂuorophotometer (Bio-Rad Laboratories
GmbH, München, Germany). The fluoro-
metric analysis of the resultant product resoruﬁn
was done with an excitation at 530 nm and an
emission wave length of 585 nm. Calibration of
the system was performed with resoruﬁn and an
appropriate standard curve with a concentra-
tion range of up to 100 nM.
Statistical analysis. We used the Mann-
Whitney U test for intergroup comparisons. A
p-value < 0.05 was considered statistically sig-
niﬁcant. Unless otherwise stated, the data are
expressed as median and range or as individual
results. 
Results
Subject characteristics and BAL data. The
clinical characteristics of the study subjects are
given in Table 1. There was no signiﬁcant dif-
ference in FEV1 (% predicted) and FEV1/
forced vital capacity (FVC) between smokers
and nonsmokers. 
Recovery of BAL fluid did not differ
between smokers and nonsmokers. The total
cell count in BAL fluid from smokers was
nearly double the cell count in nonsmokers
(p < 0.01). This was mainly due to higher
numbers of macrophages and neutrophils.
We found no significant differences in the
absolute counts of lymphocytes and eosino-
phils in BAL samples between smokers and
nonsmokers (Table 2). 
Gene expression of CYPs and FMOs.
Expression of CYP1A2, CYP2C8, CYP2C18,
CYP2C19, CYP2D6, CYP3A7, CYP4A11,
FMO1, and FMO3 was below the limit of
detection (LOD) in all investigated samples
(data not shown).
Transcript profiling in BAL cells.
Expression of CYP1A1 (p < 0.01), CYP1B1
(p < 0.001), and CYP2S1 (p < 0.001) was
higher in BAL cells from smokers compared
with those of nonsmokers (Figure 1), whereas
expression of CYP2B6/7 (p < 0.01) and
CYP3A5 (p < 0.001) was lower; expression of
CYP2A6/7, CYP2E1, CYP2C9, CYP2J2, and
FMO5 was not altered. CYP2F1 transcripts
were detected in 3 of 10 nonsmokers and in
3 of 8 smokers, but the amount was too small
for semiquantitative analysis (data not
shown). Similarly, CYP4B1 was detected in
5 smokers and 1 nonsmoker, and CYP3A4
was detected in 2 nonsmokers but was
< LOD in smokers (data not shown).
Transcript profiling in BBs. In smokers,
expression of CYP1A1 (p < 0.05), CYP1B1
(p < 0.001), and CYP2C9 (p < 0.05) was
increased (p < 0.05) compared with non-
smokers, and there was a trend toward
increased expression of CYP3A5 (p = 0.0545;
Figure 1); however, the expression of CYP2J2
was significantly (p < 0.05) repressed.
Xenobiotic metabolizing enzymes in lung tissue of smokers
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Table 3. Oligonucleotide primers and gene regulation in BAL cells and BB samples.
Accession no. Gene Forward primer (5´–3´) Reverse primer (5´–3´) Product length (bp) BAL BB
CYPs
D01150 CYP1A1 TCACAGACACAGCCTGATTGAG GATGGGTTGACCCATAGCTT 432 ↑↑
NM_000104.2 CYP1B1 GCAGAATTGGATCAGGTCGT TGGTCAGGTCCTTGTTGATG 301 ↑↑
M38504 CYP1A2 TGGCTTCTACATCCCCAAGAAAT TTCATGGTCAGCCCGTAGAT 308
U22027 CYP2A6/7 GTGTGGACATGATGCCGT AGGACTTGAGGCGGAAGT 1,151
X13494 CYP2B6/7 CCATACACAGAGGCAGTCAT GGTGTCAGATCGATGTCTTC 357 ↓
XM_050922 CYP2C8 GATCATGTAATTGGCAGACACA CCTGCTGAGAAAGGCATGAAG 311
XM_050918 CYP2C9 AGCTTGGAAAACACTGCAGT CCTGCTGAGAAAGGCATGAAG 437 ↑
NM_000772 CYP2C18 CTGTAACTGATATGTTTGGG CCTGCTGAGAAAGGCATGAAG 431
NM_000769 CYP2C19 GTAATCACTGCAGCTGACTTAC CCTGCTGAGAAAGGCATGAAG 431
M33189 CYP2D6 TGATGAGAACCTGCGCATAG ACCGATGACAGGTTGGTGAT 332
AF084225 CYP2E1 AGCACAACTCTGAGATATGG ATAGTCACTGTACTTGAACT 365
J02906 CYP2F1 ATGAACTTGCCGCACCGCGT ACAGGCTCCACTTACGGTGC 283
AF272142 CYP2J2 CCCACCAAACTCTCTTCAGC CATTCTCTGCACCTCATGGA 389 ↓
AF335278 CYP2S1 ACCCCAACATCTTCAAGCAC TTCATCTGGTCTGCGTGGT 312 ↑
X12387 CYP3A4 CCAAGCTATGCTCTTCACCG TCAGGCTCCACTTACGGTGC 323
L26985 CYP3A5 TGTCCAGCAGAAACTGCAAA TTGAAGAAGTCCTTGCGTGTC 472 ↓
NM 000765.1 CYP3A7 CTATGATACTGTGCTACAGT TCAGGCTCCACTTACGGTCT 474
AF208532 CYP4A11 CAAGTGACCTCCCTGCTCAT CTGATCTCCCCAGAATCACC 280
NM 000779.1 CYP4B1 TGACCATGTGCATCAAAGGAG AAAGCCATTCTTGGAGCGCA 397
Other drug-metabolizing enzymes
NM_000120 EPHX1 TGATGAGGGAGAGCGGGCTAC TCAGCAGGTCGTCCAGGGAG 227 ↑↓
NM_002021 FMO1 GCTGTTCGAGTCCTGAAAGG GCCAAAGAAGACGGTCAGAG 234
NM_006894 FMO3 GGCAGGGCTAGCATTTACAA GATGTCCGGAACAAACCATT 301
NM_001461 FMO5 CTCTCAGTTTCATATTGCCCAG ACATTATTTCTCTTATCTCTCAGG 400
NM_000846 GSTA2 GCCCAAGCTCCACTACTTCA GCAAGCTTGGCATCTTTTTC 354 ↑
NM_000561 GSTM1 TTCCCAATCTGCCCTACTTG GGGCTCAAATATACGGTGGA 347 ↑↑
XM_040116 GSTP1 ACCTCCGCTGCAAATACATC GGGAGGTTCACGTACTCAGG 313 ↓
XM_003547 UGT2A1 TTGGCCAATGGAAGGTAGTC TCCTGAGACACCATGTGGAA 297
Nuclear transcription factors
NM_001621 AHR CTGCCTTTCCCACAAGATGT GAAATTCAGCTCGGTCTTCG 352
NM_005122 NR1I3 GTCATGGCCAGTAGGGAAGA GTCCGGATCAGCTCTTCTTG 350 ↑
M10901 NR3C1 GCTCTGGGGTGGAGATCATA TCCTTCCCTCTTGACAATGG 300 ↑
U22662 NR1H3 TCAACCCCATCTTCGAGTTC GGGGACAGAACAGTCATTCG 351
AF061056 NR1I2 TTGTTCGGCATCACAGGTAG GGGATCTGAGGGATTTCTCC 351
Housekeeping gene
NM_021130 Cyclophilin CTTGCCATTCCTGGACCCAA TTTCGTGCTCTGAGCACTGG 347
Accession numbers from GenBank (2005). Arrows indicate up- or down-regulation of signiﬁcantly affected genes.Expression of CYP2B6/7, CYP2E1, CYP2F1,
CYP2S1, CYP4B1, and FMO5 was similar to
that of nonsmokers. CYP2A6/7 transcripts
were detected in 2 of 10 nonsmokers and 3 of
8 smokers (data not shown). CYP3A4 was
< LOD in all BBs investigated.
Gene expression of EPHX1, GSTs, and
UGTs. In BAL cells of smokers, gene expres-
sion of EPHX1 and GSTP1 was signiﬁcantly
higher that that of nonsmokers, whereas
expression of the UGT2A1 gene was signifi-
cantly lower (p < 0.001) (Figure 2). Expression
of GSTA2 and GSTM1 was not different
between the study groups (Figure 2).
Further, in BBs taken from smokers,
expression of EPHX1 was signiﬁcantly lower
(p < 0.001), whereas the expression of GSTA2
and GSTP1 were up to triple that in non-
smokers. Expression of GSTM1 and UGT2A1
was not significantly different in BBs of the
two groups (Figure 2).
Gene expression of nuclear receptors.
Gene expression of LXR (p < 0.001) and GR
(p < 0.01) in BAL cells of smokers (Figure 2)
was up to three times that of nonsmokers,
whereas expression of the cytosolic AHR and
PXR was similar. The expression of AHR,
LXR, PXR and GR was not different in BBs
of both study groups. Expression of CAR was
< LOD in all samples studied.
Enzyme activity of CYP1A1 and CYP1B1.
7-Ethoxyresorufin served as substrate for
CYP1A1 and CYP1B1. In BAL cells derived
from smokers, EROD activity was up to 3-fold
that of nonsmokers (p < 0.05; Figure 3), but
glucuronides were < LOD, as determined by
β-glucuronidase treatment.
Discussion
In this study we aimed to investigate the regu-
lation of gene expression of major human
pulmonary xenobiotic metabolizing enzymes
as well as regulatory nuclear transcription fac-
tors in smoking and nonsmoking healthy
volunteers. Differences were observed when
we compared BAL cells and BBs of smokers
and nonsmokers. Our findings provide new
insight into lung tissue–specific responses to
tobacco smoke as detailed below. 
Effects of tobacco smoke on pulmonary
xenobiotic metabolizing enzymes. Lung tissue
and cell types within the lung differ in their
capacity to oxidize xenobiotics (Hecht 1999)
because CYPs are not uniformly expressed
(Ding and Karminsky 2003). As the majority
of airborne toxicants enter the body through
the respiratory tract, the pulmonary epithelium
is exposed to high concentrations before sys-
temic circulation, which, in turn, requires an
effective local defense system. Our ﬁndings of a
simultaneous induction of CYP1A1 and
CYP1B1 in different lung compartments after
exposure to tobacco smoke demonstrate
up-regulation of the pulmonary enzyme system
and agree well with other reports (McLemore
et al. 1990). Regulation of CYP1A1 and
CYP1B1 is not fully understood, but transcrip-
tional activation by the AHR constitutes a
major mechanism. Upon translocation into the
nucleus, the AHR forms a heterodimer with its
nuclear counterpart ARNT (AHR nuclear
translocator) and drives gene expression of the
AHR-responsible gene family, including
CYP1A1 and CYP1B1 (Borlak and Thum
2001). Thus, the strong induction of CYP1A1
and CYP1B1 can be explained, at least in part,
in terms of AHR-mediated transcriptional
activation. Although we did not observe
changes of the AHR at the gene expression
level, Martey et al. (2005) recently reported
that cigarette smoke extract led to an activa-
tion of the AHR in cultured human lung
fibroblasts based on induced nuclear trans-
location of the AHR (Martey et al. 2005). The
observed up-regulation of AHR-responsive
genes in lung tissue of smokers is likely medi-
ated by the activation of AHR. The present
study does, however, contradict the findings
Thum et al.
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Figure 1. Gene expression of various CYPs in BAL cells and BB material obtained from nonsmokers (n = 10)
and smokers (n=8). NS, not significant. Data are represented as plots from individual volunteers, with
solid lines indicating medians. Results are presented as the ratio of the gene of interest/cyclophilin; only
signﬁcantly altered genes are shown.
*p < 0.05. **p < 0.01. ***p < 0.001.
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of Anttila et al. (1991), who did not find
CYP1A1 expression in alveolar macrophages,
regardless of smoking status. This may be due
to different experimental approaches because
Anttila et al. employed immunohisto-
chemistry, whereas we used a sensitive
RT-PCR method determine CYP1A1 and
CYP1B1 expression and a ﬂuorometric assay
to demonstrate increased activity of the coded
enzymes. Indeed, Willey et al. (1996) were
initially unable to detect CYP1A1 expression
in alveolar macrophages, but upon application
of more sensitive techniques these investigator
were able to detect CYP1A1 gene expression
(Willey et al. 1997).
CYP2A enzymes metabolize a variety of
carcinogens including 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK), which can
lead to the development of lung cancer
(Koskela et al. 1999). In the present study, we
detected expression of CYP2A6/7 in both
alveolar macrophages and bronchial biopsy
material, but we did not ﬁnd any difference in
regard to smoking status. This contrasts the
ﬁnding of Crawford et al. (1998), who demon-
strated repression of CYP2A6/7 in human
bronchial epithelial cells of smokers. The
somewhat high interindividual variation of
CYP2A6/7 gene expression observed in the pre-
sent study and in the study of Crawford et al.
(1998) make comparison of the data difﬁcult.
We also observed signiﬁcant induction of
CYP2S1 in BAL cells of smokers. Expression of
CYP2S1 in lung tissue has been previously
reported (Rylander et al. 2001), but regulation
by cigarette smoke has not been determined so
far. One study (Rivera et al. 2002) demon-
strated inducibility of CYP2S1 in mouse lungs
after systemic administration of dioxins. The
observed induction of CYP1A1 and CYP2S1
in bronchoalveolar macrophages and bronchial
biopsies of smokers is of importance because of
their contribution to the metabolic activation
of tobacco smoke components, namely poly-
cyclic aromatic hydrocarbons, which can lead
to the development of lung cancer (Georgiadis
et al. 2005).
CYP2B6/7 and CYP3A5 play an impor-
tant role in the metabolic activation of NNK
and of benzo[a]pyrene (Code et al. 1997;
Hecht 1999), but transcript levels and enzyme
activity were repressed in BAL cells derived
from smokers. Previously, Hukkanen et al.
(2003) demonstrated decreased CYP3A5
expression in alveolar macrophages of smokers.
We now extend the findings of Hukkanen
et al. (2003) to BBs and report a trend toward
increased CYP3A5 expression in smokers
(p < 0.0545), which could result in local
metabolic activation of carcinogens. Notably,
the CYP3A family of monooxygenases plays a
key role in pulmonary drug metabolism.
Inhaled drugs, such as salmeterol, tiotropium,
theophylline, or glucocorticoids (e.g., budeso-
nide, prednisone), with an established role in
chronic obstructive pulmonary disease or
asthma treatment (Global Initiative for
Asthma 2005; Global Initiative for Chronic
Obstructive Lung Disease 2005) are sub-
strates for CYP3A isoforms (Jonsson et al.
Figure 2. Gene expression of FMO5, various phase II enzymes, and key regulatory transcription factors in
BAL cells and BB material obtained from nonsmokers (n = 10) and smokers (n = 8). NS, not significant.
Data are represented as plots from individual volunteers, with solid lines indicating  medians. Results are
presented as the ratio of the gene of interest/cyclophilin; only signiﬁcantly altered genes are shown. 
*p < 0.05. **p < 0.01. ***p = < 0.001.
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Figure 3. Metabolism of 7-ethoxyresorufin in BAL
cells obtained from nonsmokers (n = 10) and
smokers (n = 8) with and without glucuronidase
treatment. Data represent mean ± SE of the indi-
vidual incubation experiments, with approximately
100,000 cells per experiment. 
*p < 0.05.
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*1995; Zevin and Benowitz 1999). Therefore,
modulation of CYP3A enzyme activity in
smokers may require dose adjustment for
some inhaled drugs. 
Furthermore, the CYP epoxygenases
CYP2C and CYP2J2 are key players in the
metabolism of arachidonic acid, resulting in
the production of epoxyeicosatrienoic acids,
some of which affect vascular and bronchial
smooth muscle tone (Fisslthaler et al. 1999;
Thum and Borlak 2004; Zeldin et al. 1995).
In the present study, we observed reduced
expression of CYP2J2 in BBs of smokers,
whereas CYP2C9 was signiﬁcantly induced in
this lung compartment. This shift in the
expression of the CYP epoxygenase gene might
alter production of epoxy fatty acids, some of
which are considered to be signalling molecules
affecting vascular- and smooth muscle cell
tone. Undoubtedly, future studies are needed
to determine the regulation and the role of
epoxyeicosatrienoic acids in smokers. 
In addition, genetic variability in the coding
of various CYP genes may affect enzyme activ-
ity (reviewed by Daly et al. 1994; Ingelman-
Sundberg 2001). Likewise, changes in the
expression of CYP transcripts may influence
an individual’s capacity to convert different
precarcinogenic compounds into their ulti-
mate carcinogens; therefore, these CYP tran-
scripts are of major importance for an
individual’s susceptibility of developing chem-
ically induced cancer. Certain CYP mono-
oxygenases have an established role in an
activation of precarcinogens to ultimate car-
cinogens of inhaled tobacco smoke toxicants
(e.g., CYP1A1, CYP1A2, CYP1B1, CYP2E1,
CYP3A4). The simultaneous induction of
CYP1A1 and CYP1B1 in both types of lung
cells obtained from BAL and pulmonary
epithelial cells after smoking cigarettes, as
found in the present study, may therefore
enhance an individual susceptibility for chemi-
cally induced lung cancer.
In addition, expression of EPHX1 was
increased in BAL cells of smokers, but
decreased in BBs. This is important because
in the absence of EPHX1 the tobacco smoke
carcinogen benzo[a]pyrene is primarily
metabolized to the noncarcinogenic 7,8-benzo-
phenolic product (Shou et al. 1994). Bartsch
et al. (1992) observed a signiﬁcant increase in
the activity of pulmonary EPHX1 within
smokers, but EPHX1 activity was determined
in preparations of parenchymal lung tissue,
which consists of many different cell types.
Besides, the lung tissue specimens were taken
from patients with either lung cancer or non-
neoplastic lung diseases. Thus, a direct com-
parison between the present study and that of
Bartsch et al. (1992) cannot be made. Our
results demonstrate that enzyme activity of
EPHX1 can be expressed differently in two
lung tissue compartments. 
We also observed induction of the carcino-
gen-metabolizing enzymes GSTP1 in BAL cells
and BBs and GSTA2 in BBs from smokers.
This is likely an adaptive response to chronic
exposure to tobacco smoke components.
GSTP1 overexpression inhibited cytotoxic
effects of cigarette smoke extract on human
fibroblast-derived cells and depletion of
GSTP1-induced apoptosis in lung ﬁbroblasts
(Ishii et al. 2001, 2003). Moreover, Crawford
et al. (2000) showed that mRNA levels of
GSTs expressed by bronchial epithelial cells
from patients with bronchogenic carcinoma
are signiﬁcantly lower compared with subjects
without carcinoma. Thus, increased expression
of GSTP1 in healthy smokers might protect
against accumulation of carcinogens. 
Effects on nuclear receptors. GR and LXR
were significantly up-regulated in BAL cells,
but no clear correlation between CYP mono-
oxygenases and nuclear receptor gene expres-
sion was observed. However, the up-regulation
of GR ﬁts well to the increased expression of
CYP2C9 because GR plays an important role
in transcriptional regulation of the CYP2C9
gene (Gerbal-Chaloin et al. 2002). CYP regu-
lation is, in most cases, not dependent only on
a speciﬁc nuclear factor, but requires a com-
plex network of interacting factors (Waxman
1999). 
Study limitations. We did not recruit for a
sex-balanced study group; for example, 8 of 10
were females in the nonsmoking group,
whereas 7 of 8 were males in the smoking
group. Nonetheless, when gene expression was
compared between men and women, we found
no signiﬁcant differences. Furthermore, within
different lung tissue compartments, we
observed opposite effects in expression of cer-
tain genes (i.e., CYP3A5, EPHX1) for smokers,
but these were independent of the sex.
Although drug administration before the
bronchoscopic procedures was strictly con-
trolled, we cannot rule out minor effects of the
drugs used (e.g., midazolam, lidocain,
atropine) on gene expression within lung tis-
sue. Notably, the same drugs were given to
both smokers and nonsmokers, usually
≤ 15 min before the bronchoscopic proce-
dures. This short interval makes major effects
on gene expression unlikely.
Conclusions
We observed profound effects of tobacco
smoke exposure in BBs and BAL cells of vol-
unteers and found CYP1A1, CYP1B1, and
GSTP1 to be up-regulated in BBs and alveolar
macrophages of smokers, whereas others tran-
scripts were differentially expressed and, in
some cases, even oppositely regulated (i.e.,
CYP3A5, EPHX1). Differences in the expres-
sion of xenobiotic metabolizing enzymes may
suggest local and tissue-speciﬁc susceptibility
in metabolically activated toxicity.
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